drug
IMATINIB
updated 4mo agoby DR REDDYS
community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying IMATINIB
- phase2Frontline Asciminib Combination in Chronic Phase CML
- phase2KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
- phase4Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
- phase4Asciminib Roll-over Study
- phase3A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
- phase3A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
- phase2Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
- phase3A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
News(2)
- How Reimagined Research Endeavors Intersect With Dignified End-of-Life Care: With D. Ross Camidge, MD, PhD; and Charles D. Blanke, MD, FACP, FASCODrs Camidge and Blanke discuss Dr Blanke's career path from pioneering targeted cancer therapies to becoming a leading advocate for medical aid in dying.onclive · 4mo ago
- Dr Mauro on the Significance of Alternative TKI Formulations in CMLMichael Mauro, MD, details the FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in chronic myeloid leukemia.onclive · 4mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that